CBN and Sleep: What a Randomised Study Found
CBN (cannabinol) is increasingly used in products marketed for night-time routines. A double-blind, randomised, placebo-controlled study examined CBN, with and without CBD, in adults reporting poor sleep.
Study Design
The trial included adults aged 18–55 and compared several cannabinoid formulations with placebo. Outcomes included self-reported sleep quality, sleep onset, awakenings, sleep disturbance and daytime fatigue.
What the Study Reported
The 20 mg CBN group showed a signal for fewer night-time awakenings and lower sleep disturbance. However, the primary sleep-quality result was not statistically significant versus placebo. Adding CBD did not clearly improve outcomes over CBN alone.
What the Study Does Not Prove
- It does not establish CBN as a treatment for insomnia.
- It does not show that every CBN product will produce the same result.
- It does not establish long-term effectiveness or safety.
- It does not justify extrapolating the study dose to retail dosing advice.
Safety
No serious adverse events were reported in the study, but non-serious effects included drowsiness, headache and sleep-related complaints. A single trial cannot establish long-term safety across different populations or medicines.
What This Means for CBN Products
CBN is a reasonable subject for further sleep research, but marketing should stay cautious. Night-time positioning, flavour, concentration and cannabinoid profile are product characteristics; they are not proof that a product will improve sleep.
When to Seek Medical Advice
Persistent insomnia, loud snoring, breathing pauses, severe daytime sleepiness or sleep problems linked to mental-health symptoms should be discussed with a healthcare professional rather than managed only with supplements.
